Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia, Ventilator-Associated | 8 | 2019 | 41 | 2.920 |
Why?
|
| Sepsis | 8 | 2024 | 478 | 2.380 |
Why?
|
| Respiratory Insufficiency | 3 | 2022 | 226 | 1.900 |
Why?
|
| Shock, Septic | 4 | 2024 | 146 | 1.640 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 180 | 1.200 |
Why?
|
| Intensive Care Units | 8 | 2022 | 490 | 1.120 |
Why?
|
| Anti-Bacterial Agents | 11 | 2024 | 2428 | 1.090 |
Why?
|
| Microbiota | 3 | 2021 | 388 | 1.040 |
Why?
|
| Bacteremia | 2 | 2020 | 407 | 0.880 |
Why?
|
| Pneumonia, Bacterial | 3 | 2019 | 76 | 0.870 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2021 | 142 | 0.820 |
Why?
|
| Noninvasive Ventilation | 1 | 2022 | 29 | 0.770 |
Why?
|
| Syphilis | 1 | 2022 | 96 | 0.740 |
Why?
|
| Coronavirus | 1 | 2020 | 25 | 0.700 |
Why?
|
| Dysbiosis | 2 | 2020 | 122 | 0.700 |
Why?
|
| Communicable Diseases | 3 | 2021 | 160 | 0.650 |
Why?
|
| Aerosols | 1 | 2019 | 65 | 0.630 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 357 | 0.600 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 371 | 0.600 |
Why?
|
| Adenosine Monophosphate | 4 | 2022 | 42 | 0.590 |
Why?
|
| Pandemics | 4 | 2021 | 1108 | 0.570 |
Why?
|
| Respiration, Artificial | 6 | 2021 | 462 | 0.570 |
Why?
|
| Alanine | 4 | 2022 | 183 | 0.570 |
Why?
|
| Critical Illness | 2 | 2022 | 602 | 0.560 |
Why?
|
| Isoptera | 1 | 2017 | 4 | 0.560 |
Why?
|
| Vitreous Hemorrhage | 1 | 2017 | 9 | 0.560 |
Why?
|
| Antimicrobial Stewardship | 1 | 2019 | 84 | 0.560 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 558 | 0.550 |
Why?
|
| Ventriculostomy | 1 | 2017 | 35 | 0.550 |
Why?
|
| Antiviral Agents | 5 | 2022 | 750 | 0.540 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2017 | 54 | 0.540 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2017 | 70 | 0.530 |
Why?
|
| Intracranial Hypertension | 1 | 2017 | 125 | 0.490 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 215 | 0.470 |
Why?
|
| Coinfection | 1 | 2016 | 169 | 0.460 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 235 | 0.450 |
Why?
|
| Humans | 36 | 2024 | 124906 | 0.450 |
Why?
|
| Double-Blind Method | 7 | 2022 | 1645 | 0.440 |
Why?
|
| Treatment Outcome | 8 | 2022 | 12405 | 0.420 |
Why?
|
| Critical Care | 2 | 2022 | 656 | 0.380 |
Why?
|
| Poisoning | 1 | 2010 | 15 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2016 | 519 | 0.340 |
Why?
|
| Adrenal Insufficiency | 1 | 2010 | 28 | 0.330 |
Why?
|
| Bacterial Toxins | 1 | 2010 | 175 | 0.330 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 698 | 0.320 |
Why?
|
| Cardiovascular System | 1 | 2010 | 106 | 0.320 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 738 | 0.310 |
Why?
|
| Antigens, Bacterial | 1 | 2010 | 314 | 0.300 |
Why?
|
| Survival Analysis | 2 | 2014 | 1507 | 0.290 |
Why?
|
| Societies | 2 | 2017 | 25 | 0.270 |
Why?
|
| Ultrasonography | 2 | 2021 | 933 | 0.230 |
Why?
|
| Azetidines | 2 | 2022 | 58 | 0.220 |
Why?
|
| Purines | 2 | 2022 | 114 | 0.220 |
Why?
|
| Kidney | 1 | 2010 | 1356 | 0.220 |
Why?
|
| Cross Infection | 2 | 2016 | 323 | 0.210 |
Why?
|
| Sulfonamides | 2 | 2022 | 268 | 0.200 |
Why?
|
| Interferon beta-1a | 1 | 2021 | 18 | 0.190 |
Why?
|
| Urology | 1 | 2022 | 75 | 0.190 |
Why?
|
| RNA, Viral | 2 | 2021 | 538 | 0.190 |
Why?
|
| Dexamethasone | 4 | 2022 | 275 | 0.190 |
Why?
|
| Pyrazoles | 2 | 2022 | 305 | 0.190 |
Why?
|
| Dogs | 3 | 2014 | 768 | 0.190 |
Why?
|
| New York | 1 | 2021 | 68 | 0.180 |
Why?
|
| Immunization, Passive | 1 | 2021 | 120 | 0.180 |
Why?
|
| Pharynx | 1 | 2020 | 64 | 0.170 |
Why?
|
| Saliva | 1 | 2021 | 114 | 0.170 |
Why?
|
| Nose | 1 | 2021 | 93 | 0.170 |
Why?
|
| Respiratory System | 1 | 2020 | 97 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 287 | 0.170 |
Why?
|
| Mouth | 1 | 2020 | 61 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2021 | 142 | 0.170 |
Why?
|
| Amikacin | 1 | 2019 | 24 | 0.170 |
Why?
|
| Resuscitation | 1 | 2021 | 250 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2022 | 1397 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2021 | 851 | 0.140 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 98 | 0.140 |
Why?
|
| Enterobacteriaceae | 1 | 2017 | 35 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 27 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2017 | 121 | 0.130 |
Why?
|
| United States | 7 | 2024 | 10909 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 460 | 0.130 |
Why?
|
| Terminology as Topic | 1 | 2018 | 222 | 0.130 |
Why?
|
| Adult | 10 | 2024 | 29576 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 205 | 0.120 |
Why?
|
| Probiotics | 1 | 2018 | 213 | 0.120 |
Why?
|
| beta-Lactamases | 1 | 2017 | 198 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 2014 | 36 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2014 | 63 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 2018 | 245 | 0.110 |
Why?
|
| Oxygen | 3 | 2022 | 553 | 0.110 |
Why?
|
| Research | 1 | 2016 | 263 | 0.110 |
Why?
|
| Dog Diseases | 1 | 2014 | 50 | 0.110 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2014 | 76 | 0.110 |
Why?
|
| Male | 8 | 2022 | 61395 | 0.110 |
Why?
|
| Hydrocortisone | 2 | 2014 | 217 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 198 | 0.100 |
Why?
|
| Transaminases | 1 | 2010 | 32 | 0.090 |
Why?
|
| Adrenal Glands | 1 | 2010 | 43 | 0.080 |
Why?
|
| Vascular Resistance | 1 | 2010 | 189 | 0.080 |
Why?
|
| Aldosterone | 1 | 2010 | 60 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 90 | 0.080 |
Why?
|
| Urea | 1 | 2010 | 226 | 0.080 |
Why?
|
| Propofol | 1 | 2010 | 43 | 0.080 |
Why?
|
| Conscious Sedation | 1 | 2010 | 62 | 0.080 |
Why?
|
| Middle Aged | 5 | 2022 | 26879 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2021 | 367 | 0.080 |
Why?
|
| Medicare | 2 | 2024 | 424 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2096 | 0.080 |
Why?
|
| Creatinine | 1 | 2010 | 390 | 0.080 |
Why?
|
| Animals | 4 | 2017 | 34057 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 136 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 590 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 172 | 0.070 |
Why?
|
| Female | 6 | 2022 | 66678 | 0.070 |
Why?
|
| Aged | 5 | 2024 | 19835 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 290 | 0.070 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 87 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2016 | 134 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1364 | 0.060 |
Why?
|
| Reimbursement, Incentive | 1 | 2024 | 47 | 0.050 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2022 | 7 | 0.050 |
Why?
|
| Volunteers | 1 | 2022 | 24 | 0.050 |
Why?
|
| Risk Factors | 1 | 2017 | 10285 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 70 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2024 | 175 | 0.050 |
Why?
|
| Singapore | 1 | 2021 | 16 | 0.050 |
Why?
|
| Republic of Korea | 1 | 2021 | 37 | 0.050 |
Why?
|
| Japan | 1 | 2021 | 133 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 182 | 0.050 |
Why?
|
| Forecasting | 1 | 2022 | 351 | 0.050 |
Why?
|
| Ribonucleases | 1 | 2021 | 52 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 63 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 22 | 0.040 |
Why?
|
| Biological Transport | 1 | 2021 | 354 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4353 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 428 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 145 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 163 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 696 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 219 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 388 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 759 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 1116 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 1054 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1165 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1024 | 0.030 |
Why?
|
| Mineralocorticoids | 1 | 2014 | 8 | 0.030 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2014 | 18 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2881 | 0.030 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 612 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 3069 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 4631 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1780 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6320 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1269 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 9051 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 19343 | 0.010 |
Why?
|